Overview

Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous CR

Status:
Not yet recruiting

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

This phase II open label trial randomized patients who completed the induction with nivolumab plus ipilimumab without complete response or progressive disease will be randomized 1:1 to receive axitinib in addition to nivolumab (Arm A) or continue with nivolumab alone (Arm B).Treatment will be continued until progression of disease, unacceptable toxicity, patient's refusal, or physician decision whichever occurred first.

Phase:

Phase 2

Details

Lead Sponsor:

Consorzio Oncotech

Collaborator:

Pfizer

Treatments:

Axitinib
Nivolumab